BLTP3A (also known as UHRF1BP1) silenced CAR-T cells demonstrate elevated efficacy against High-grade serous carcinoma (HGSC)
​
Impairing BLTP3A elevates T cells activity via enhanced recycling of TCR and CAR machinery through the endosomal system.
Invention Summary:
Despite recent advances in cancer immunotherapy, objective responses remain rare. This is partly due to an incomplete understanding of the complex immunosuppressive mechanisms operating within the...
Published: 2/21/2025
|
Inventor(s): Kyle Payne, Fnu Kumari
Keywords(s):
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics, Technology Classifications > Cell Therapy
|